ADAlbert D. Donnenberg

Albert D. Donnenberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Albert D. Donnenberg has a total of 118 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Optimal transport analysis of high-dimensional flow cytometry data in immuno-oncology

    by Abida Sanjana Shemonti, Justin C. Wang, Albert D. Donnenberg, Bartek Rajwa, Patrick L. Wagner, David L. Bartlett, Bosko Popov, Evan T. Alicuben, Vera S. Donnenberg

    Introduction: Advances in single-cell and spatial profiling have enabled detailed characterization of heterogeneous samples, but analyzing this data remains challenging in settings involving multiple comparisons. While tools like UMAP and t-SNE are valuable for visualization, their stochastic, parameter-sensitive nature limits their use in longitudinal comparisons, treatment group analysis, and multicenter trials. Although OT was first described in the 19th century, the Sinkhorn algorithm makes it computationally tractable for high-dimensional data. By directly comparing distributions of cellular states, OT provides reproducible measures of change in high-dimensional space. This framework is amenable to integration with machine learning, including deep generative models. Methods: OT was applied to longitudinal data from a phase I trial of tocilizumab for cavitary malignancies (NCT 06016179). The current implementation makes use of expert-guided phenotypic population definitions and their relationships. An OT-based graph representation was created for baseline and follow-up samples. The graph layout was fixed across samples and computed from phenotypic relationships. In this implementation vertex radii are proportional to their relative abundance, allowing for rapid visual assessment of population-level increases and decreases. Graph edge thickness and color encode inter-population similarity based on the optimal transport (Sinkhorn) distance between marker expression distributions. Results: This representation enabled rapid identification of populations undergoing substantial change, such as the CD8+/IFNɣ+ population, which decreased from 63% to 17% of CD8+ T cells following treatment. Population changes across all fluorescence parameters were encoded in the graph edit distance (GED), which captures changes in population abundance and phenotypic shifts in marker space. Discussion: Future implementations can combine this expert-guided approach with unbiased clustering algorithms to enhance scalability and cross-platform harmonization. In our recently initiated clinical trials, we will apply OT to identify key shifts in tumor, immune, and stromal cell states, summarizing patient trajectories and quantitatively supporting predictive models of treatment response. Potential applications include quantifying residual disease after chemotherapy, tracking immune activation during immunotherapy, and linking host–microbiome interactions to disease progression. This approach overcomes the limitations of traditional, local-structure-optimized tools (UMAP or t-SNE) to provide a comprehensive, longitudinal view of tumor evolution and treatment response.

  • In-house manufacture of plasma-derived human AB serum for use in cellular therapeutics

    by Paige O. Mirsky, John Lister, Albert D. Donnenberg

  • Open Access

    The Tumor Environment in Peritoneal Carcinomatosis and Malignant Pleural Effusions: Implications for Therapy

    by Paige O. Mirsky, Patrick L. Wagner, Maja Mandic-Popov, Vera S. Donnenberg, Albert D. Donnenberg

    Peritoneal carcinomatosis (PC) and malignant pleural effusions (MPE) are two common complications of cancers metastatic to the respective body cavities. A PC diagnosis indicates metastasis to the tissue lining the abdominal cavity and is most common in patients with gastrointestinal and gynecological cancers. It is often accompanied by ascites, an accumulation of serous fluid in the abdomen. MPE presents as the accumulation of fluid in the space between the lungs and chest wall. It is a common terminal event in patients diagnosed with breast cancer, lung cancer, lymphoma, and mesothelial cancers, and less commonly, in a wide variety of other epithelial cancers. Due to the aggressive nature of cavitary tumors, the outcome of current treatments for both PC and MPE remains bleak. Although PC and MPE are characteristically affected by different sets of primary tumors (lung/breast/mesothelioma for MPE and gynecologic/gastrointestinal for PC), their environments share common cytokines and cellular components. Owing to the unique cytokine and chemokine content, this environment promotes aggressive tumor behavior and paradoxically both recruits and suppresses central memory and effector memory T cells. The cellular and secretomic complexity of the cavitary tumor environment renders most currently available therapeutics ineffective but also invites approaches that leverage the robust T-cell infiltrate while addressing the causes of local suppression of anti-tumor immunity. Interactions between the heterogeneous components of the tumor environment are an area of active research. We highlight the roles of the immune cell infiltrate, stromal cells, and tumor cells, and the soluble products that they secrete into their environment. A more comprehensive understanding of the cavitary tumor environment can be expected to lead to better immunotherapeutic approaches to these devastating conditions.


  • Open Access

    The Interleukin-8-CXCR1/2 Axis as a Therapeutic Target in Peritoneal Carcinomatosis

    by Christopher Sherry, Neda Dadgar, Zuqiang Liu, Yong Fan, Kunhong Xiao, Ali H. Zaidi, Vera S. Donnenberg, Albert D. Donnenberg, David L. Bartlett, Patrick L. Wagner

    Peritoneal carcinomatosis (PC) is a late-stage manifestation of abdominopelvic malignancies with poor prognosis and limited treatment options. Unique biochemical mechanisms within the peritoneal cavity play a key role in disease progression and resistance to therapy. Despite current therapies like systemic chemotherapy and cytoreductive surgery, patients frequently develop severe complications, including bowel obstruction, nutritional decline, and ascites, driving the need to address the pro-tumorigenic niche in the peritoneal cavity. The immune microenvironment in PC is marked by elevated proinflammatory mediators, such as IL-6 and IL-8, which skew the response toward innate rather than adaptive immune responses. IL-8 signaling, through its receptors CXCR1 and CXCR2, promotes neutrophil recruitment, chronic inflammation, angiogenesis, epithelial–mesenchymal transition, and immune evasion, making the IL-8/CXCR1/CXCR2 axis a potential therapeutic target in PC. Pre-clinical models provide evidence that IL-8 or CXCR1/CXCR2 blockade may be a valuable therapeutic strategy. IL-8 targeting agents such as monoclonal antibodies (BMS-986253) and small-molecule inhibitors (SX-682, AZD5069, navarixin) have shown efficacy in mitigating tumor growth and improving the efficacy of immune checkpoint inhibitors. Phase I and II trials have demonstrated encouraging safety profiles and preliminary efficacy when treating multiple abdominopelvic malignancies. In this review, we discuss the influence of the IL-8/CXCR1/CXCR2 axis within the peritoneal immune environment in PC and highlight recent work using IL-8 or CXCR1/CXCR2 blockade as a therapeutic strategy for PC. Continued research into the peritoneal immune microenvironment and the development of targeted therapies are essential for improving the management and prognosis of PC, potentially enhancing antitumor immunity and patient outcomes.


  • Fast tumor-infiltrating lymphocytes (TILs): rapid manufacture of an adoptive cellular therapeutic from pleural infiltrating T cells for intrapleural administration

    by Vera S. Donnenberg, John Lister, Charlene L. Briedenbaugh, Patrick L. Wagner, David L. Bartlett, Albert D. Donnenberg


  • Open Access

    Fusobacterium nucleatum Is Associated with Tumor Characteristics, Immune Microenvironment, and Survival in Appendiceal Cancer

    by Christopher Sherry, Neda Dadgar, Hyun Park, Chelsea Knotts, Erin Grayhack, Rose Blodgett, Kunhong Xiao, Ashten N. Omstead, Albert D. Donnenberg, David L. Bartlett, et al.

    Emerging evidence highlights the role of the tumor microbiome, including Fusobacterium nucleatum (Fn), in a wide range of gastrointestinal cancers. Fn purportedly contributes to tumorigenesis by activating oncogenic pathways and modulating immune responses. Although the prevalence and impact of Fn has been extensively studied in colorectal cancer, no previous systematic or in situ studies have been performed in appendiceal cancer (AC). The aim of this study was to evaluate the prevalence and association of Fn density in AC with clinical factors and oncologic outcomes. Archival tissue from 54 patients with AC was assessed for Fn density using RNA in situ hybridization. Clinicopathological variables were obtained for each case through electronic medical record review, and the immune microenvironment was characterized in each case using immunohistochemistry to quantify CD3+ and CD8+ T lymphocytes and M1-/M2-like tumor-associated macrophages. In AC, Fn density was associated with patient age, tumor grade, and histologic subtype. Fn was negatively associated with CD3+ and CD8+ T lymphocytes and positively associated with M2-like TAMs in low-grade AC. Interestingly, tumor Fn content was associated with better overall and progression-free survival, even when controlling for tumor grade. In this exploratory study, we found that Fn is prevalent in AC. Fn is associated with a number of clinical, pathologic, immunologic, and prognostic variables in AC that are distinct from the corresponding observed associations in colorectal cancer. Further research is warranted to validate these findings and explore the mechanistic contributions of Fn to AC pathogenesis or immune response.


  • Open Access

    A common secretomic signature across epithelial cancers metastatic to the pleura supports IL-6 axis therapeutic targeting

    by Vera S. Donnenberg, James D. Luketich, Bosko Popov, David L. Bartlett, Albert D. Donnenberg

    Background: Many cancers metastasize to the pleura, resulting in effusions that cause dyspnea and discomfort. Regardless of the tissue of origin, pleural malignancies are aggressive and uniformly fatal, with no treatment shown to prolong life. The pleural mesothelial monolayer is joined by tight junctions forming a contained bioreactor-like space, concentrating cytokines and chemokines secreted by the mesothelium, tumor, and infiltrating immune cells. This space represents a unique environment that profoundly influences tumor and immune cell behavior. Defining the pleural secretome is an important step in the rational development localized intrapleural immunotherapy.Method: We measured cytokine/chemokine content of 252 malignant pleural effusion (MPE) samples across multiple cancers using a 40-analyte panel and Luminex multiplexing technology.Results: Eleven analytes were consistently present in concentrations ≥ 10.0 pM: CXCL10/IP10 (geometric mean = 672.3 pM), CCL2/MCP1 (562.9 pM), sIL-6Rα (403.1 pM), IL-6 (137.6 pM), CXCL1/GRO (80.3 pM), TGFβ1 (76.8 pM), CCL22/MDC (54.8 pM), CXCL8/IL-8 (29.2 pM), CCL11/Eotaxin (12.6 pM), IL-10 (11.3 pM), and G-CSF (11.0 pM). All are capable of mediating chemotaxis, promotion of epithelial to mesenchymal transition, or immunosuppression, and many of are reportedly downstream of a pro-inflammatory cytokine cascade mediated by cytokine IL-6 and its soluble receptor.Conclusion: The data indicate high concentrations of several cytokines and chemokines across epithelial cancers metastatic to the pleura and support the contention that the pleural environment is the major factor responsible for the clinical course of MPE across cancer types. A sIL-6Rα to IL-6 molar ratio of 2.7 ensures that virtually all epithelial, immune and vascular endothelial cells in the pleural environment are affected by IL-6 signaling. The central role likely played by IL-6 in the pathogenesis of MPE argues in favor of a therapeutic approach targeting the IL-6/IL-6R axis.


  • Predicting the CD34 content of mobilized peripheral blood leukapheresis products: single institution experience over 20 years

    by Yaşa G. Mutlu, Joan Sevcik, Joseph E. Kiss, John Lister, Linda R. Moore, Albert D. Donnenberg


  • Open Access

    A maladaptive pleural environment suppresses preexisting anti-tumor activity of pleural infiltrating T cells

    by Vera S. Donnenberg, James D. Luketich, Ibrahim Sultan, John Lister, David L. Bartlett, Sohini Ghosh, Albert D. Donnenberg

    Introduction: Treatment options for patients with malignant pleural effusions (MPE) are limited due, at least in part, to the unique environment of the pleural space, which drives an aggressive tumor state and governs the behavior of infiltrating immune cells. Modulation of the pleural environment may be a necessary step toward the development of effective treatments. We examine immune checkpoint molecule (ICM) expression on pleural T cells, the secretomes of pleural fluid, pleural infiltrating T cells (PIT), and ability to activate PIT ex vivo.Methods: ICM expression was determined on freshly drained and in vitro activated PIT from breast, lung and renal cell cancer. Secretomics (63 analytes) of activated PIT, primary tumor cultures and MPE fluid was determined using Luminex technology. Complementary digital spatial proteomic profiling (42 analytes) of CD45+ MPE cells was done using the Nanostring GeoMx platform. Cytolytic activity was measured against autologous tumor targets.Results: ICM expression was low on freshy isolated PIT; regulatory T cells (T-reg) were not detectable by GeoMx. In vitro activated PIT coexpressed PD-1, LAG-3 and TIGIT but were highly cytotoxic against autologous tumor and uniquely secreted cytokines and chemokines in the > 100 pM range. These included CCL4, CCL3, granzyme B, IL-13, TNFα, IL-2 IFNγ, GM-CSF, and perforin. Activated PIT also secreted high levels of IL-6, IL-8 and sIL-6Rα, which contribute to polarization of the pleural environment toward wound healing and the epithelial to mesenchymal transition. Addition of IL-6Rα antagonist to cultures reversed tumor EMT but did not alter PIT activation, cytokine secretion or cytotoxicity.Discussion: Despite the negative environment, immune effector cells are plentiful, persist in MPE in a quiescent state, and are easily activated and expanded in culture. Low expression of ICM on native PIT may explain reported lack of responsiveness to immune checkpoint blockade. The potent cytotoxic activity of activated PIT and a proof-of-concept clinical scale GMP-expansion experiment support their promise as a cellular therapeutic. We expect that a successful approach will require combining cellular therapy with pleural conditioning using immune checkpoint blockers together with inhibitors of upstream master cytokines such as the IL-6/IL-6R axis.


  • Optimizing interpretation of survival studies of fresh and aged transfused biotin‐labeled RBCs

    by Albert D. Donnenberg, Daniel B. Kim‐Shapiro, Tamir Kanias, Linda R. Moore, Joseph E. Kiss, Janet S. Lee, Zeyu Xiong, Ling Wang, Darrell J. Triulzi, Mark T. Gladwin

    Background: Ex vivo labeling with 51chromium represents the standard method to determine red blood cell (RBC) survival after transfusion. Limitations and safety concerns spurred the development of alternative methods, including biotinylated red blood cells (BioRBC).Study Design and Methods: Autologous units of whole blood were divided equally into two bags and stored under standard blood bank conditions at 2 to 6°C (N = 4 healthy adult volunteers). One bag was biotinylated (15 μg/ml) on storage days 5 to 7 (fresh) and the other was biotinylated (3 μg/ml) on days 35 to 42 (aged). The proportion of circulating BioRBC was measured serially, and cell‐surface biotin was quantified with reference to molecules of equivalent soluble fluorochrome. Clearance kinetics were modeled by RBC age distribution at infusion (Gaussian vs. uniform) and decay over time (constant vs. exponential).Results: Data were consistent with biphasic exponential clearance of cells of uniform age. Our best estimate of BioRBC clearance (half‐life [T1/2]) was 49.7 ± 1.2 days initially, followed by more rapid clearance 82 days after transfusion (T1/2 = 15.6 ± 0.6 days). As BioRBC aged in vivo, molecules of equivalent soluble fluorochrome declined with a T1/2 of 122 ± 9 days, suggesting gradual biotin cleavage. There were no significant differences between the clearance of fresh and aged BioRBC.Conclusion: Similar clearance kinetics of fresh and aged BioRBC may be due to the extensive washing required during biotinylation. Survival kinetics consistent with cells with uniform rather than Gaussian or other non‐uniform age distributions suggest that washing, and potentially RBC culling, may extend the storage life of RBC products.